---

Endologix (Nasdaq: ELGX) developed innovative medical devices for the treatment of aortic abdominal aortic aneurysms. In 2010, Essex Woodlands made an investment in Endologix, concurrently selling its other portfolio company, Nellix Endovascular, to Endologix.

• Irvine, CA
• NASDAQ: ELGX


• Contact:
  Guido J. Neels
  

Related News

• Endologix Provides an Update on the Nellix Endovascular Aneurysm Sealing System US Regulatory Status
• Endologix Completes Patient Enrollment in the Ovation LUCY Study
• Endologix Announces CE Mark for Next-Generation Nellix(R) EndoVascular Aneurysm Sealing System
• Endologix Announces First Patients in Japan Treated with Nellix(R) EndoVascular Aneurysm System
• Endologix, Inc. and TriVascular Technologies, Inc. Complete Merger
• Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger
• Endologix Completes Patient Enrollment in the Nellix EVAS FORWARD-IDE Clinical Trial
• Endologix Reports 13% Global Revenue Growth for the Second Quarter 2014
• Endologix Achieves Revenue Milestone for the Nellix EndoVascular Aneurysm Sealing System
• Endologix Receives IDE Approval for the Nellix (R) EndoVascular Aneurysm Sealing System
• Endologix Hopes Nellix Deal is a Winning Hand
• Endologix Reports 27% and 25% Revenue Growth for the Full Year and Fourth Quarter 2012
• Endologix Announces Favorable Clinical Results for Nellix Technology